News | May 03, 2024
Moderna posts Q1 2024 revenues at US$167 million
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims
2024 full-year revenue guidance raised by US$ 2 billion
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.
The USFDA has issued 5 observations pursuant to the completion of audit
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
The QC Lab is equipped with advanced instruments to ensure rigorous quality control across all manufacturing processes
If approved in the European Union, Fruquintinib will be the first novel targeted therapy for Metastatic Colorectal Cancer regardless of biomarker status in over a decade
Subscribe To Our Newsletter & Stay Updated
